Opus Genetics (IRD) CFO Robert E. Gagnon Sells 28,000 Shares

What Happened

• Robert E. Gagnon, Chief Financial Officer of Opus Genetics, sold 28,000 shares on September 3, 2026, generating approximately $127,212. The filing lists the transaction as an open-market or private sale (code S).
• The reported weighted-average price was $4.54 per share; individual sale prices ranged from $4.29 to $4.79. This sale was partly to satisfy tax withholding on vested restricted stock units and partly executed under a Rule 10b5-1 trading plan.

Key Details

• Transaction date: 2026-09-03; filing date (Form 4): 2026-09-08 (filed 5 days after the transaction).
• Shares sold: 28,000; weighted-average price: $4.54; total proceeds reported: $127,212.
• Price range: $4.29–$4.79 across multiple transactions; the filer can provide per-price breakdown on request (see footnote).
• Notable footnotes: (F1) portion sold to cover tax withholding from RSU vesting; remainder sold under a pre-established Rule 10b5-1 plan (adopted Apr 30, 2026). (F2) weighted-average price noted and range provided.
• Shares owned after the transaction: not disclosed in the provided excerpt of the filing.
• Timeliness: The Form 4 was filed 5 days after the transaction; Form 4s are generally due within two business days, so this appears later than typical.

Context

• Sales tied to tax withholding for vested RSUs and sales under a 10b5-1 plan are generally considered routine and may not reflect the insider's current view of the company. A 10b5-1 plan is a pre-arranged program that automatically executes trades according to set parameters established when the insider was not aware of material nonpublic information.
• For retail investors, purchases by insiders are often more informative than routine sales; this transaction appears driven by tax and pre-planned selling mechanics rather than a discretionary open-market sell decision.